Minakata Kenji, Dearani Joseph A, O'Leary Patrick W, Danielson Gordon K
Division of Cardiovascular Surgery, Mayo Clinic and Foundation, Rochester, Minnesota, USA.
Ann Thorac Surg. 2005 Oct;80(4):1424-9; discussion 1429-30. doi: 10.1016/j.athoracsur.2005.03.109.
Symptomatic pediatric patients with obstructive hypertrophic cardiomyopathy (HCM) have a higher death rate (6% annually) compared with adults. Transaortic left ventricular septal myectomy provides excellent outcomes for adults with obstructive HCM. We sought to assess the effect of septal myectomy on late survival and outcome in pediatric patients with obstructive HCM.
From 1975 to 2003, 56 pediatric patients underwent septal myectomy for obstructive HCM. Mean age at diagnosis was 6.3 +/- 5.4 years. Ages at operation ranged from 2 months to 20 years (mean 11 +/- 5.6 years). Concomitant procedures included mitral valve repair (n = 7), closure of atrial septal defect (n = 3), and other (n = 5).
After myectomy, mean left ventricular outflow tract (LVOT) gradient decreased from 103 +/- 34 to 16 +/- 12 mm Hg and mean degree of mitral regurgitation decreased from 2.0 +/- 1.0 to 1.0 +/- 0.3 (both p < 0.0001). There were no early deaths. Four patients underwent elective cardioverter defibrillator implantation and 1 patient received a permanent pacemaker. Follow-up ranged up to 29 years (mean, 8.6 +/- 6.2). Cardiac reoperations were required in 8 patients: heart transplantation (n = 2), repeat myectomy (n = 2), mitral valve repair-replacement (n = 2), Konno-Rastan procedure (n = 1), and aortic valve replacement (n = 1). Age 14 years or less at operation was the only predictor of late reoperation (p = 0.017). Two patients died late; one suddenly without residual LVOT obstruction and one from chronic rejection after heart transplantation. Ninety-six percent of surviving patients were in New York Heart Association functional class I or II. Survival estimates at 5 and 10 years were 97% and 93%, respectively.
Septal myectomy is safe and effective in symptomatic pediatric patients with obstructive HCM. Late survivorship compares very favorably with the natural history of this disease.
有症状的小儿梗阻性肥厚型心肌病(HCM)患者的死亡率(每年6%)高于成人。经主动脉左心室间隔肌切除术为成人梗阻性HCM患者带来了良好的治疗效果。我们旨在评估间隔肌切除术对小儿梗阻性HCM患者晚期生存及预后的影响。
1975年至2003年,56例小儿患者因梗阻性HCM接受了间隔肌切除术。诊断时的平均年龄为6.3±5.4岁。手术年龄从2个月至20岁不等(平均11±5.6岁)。同期手术包括二尖瓣修复(n = 7)、房间隔缺损闭合术(n = 3)及其他手术(n = 5)。
肌切除术后,平均左心室流出道(LVOT)压差从103±34降至16±12 mmHg,平均二尖瓣反流程度从2.0±1.0降至1.0±0.3(均p < 0.0001)。无早期死亡病例。4例患者接受了择期心脏复律除颤器植入术,1例患者接受了永久性起搏器植入术。随访时间长达29年(平均8.6±6.2年)。8例患者需要再次进行心脏手术:心脏移植(n = 2)、再次肌切除术(n = 2)、二尖瓣修复-置换术(n = 2)、Konno-Rastan手术(n = 1)及主动脉瓣置换术(n = 1)。手术时年龄14岁及以下是晚期再次手术的唯一预测因素(p = 0.017)。2例患者晚期死亡;1例无LVOT残余梗阻突然死亡,1例因心脏移植后慢性排斥反应死亡。96%的存活患者为纽约心脏协会心功能I级或II级。5年和10年的生存估计分别为97%和93%。
间隔肌切除术对有症状的小儿梗阻性HCM患者安全有效。晚期生存率与该疾病的自然病程相比非常有利。